As Biotechnology businesses, Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Osmotica Pharmaceuticals plc||274.34M||1.25||6.40M||-0.13||0.00|
|Rexahn Pharmaceuticals Inc.||N/A||0.00||14.37M||-0.47||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Osmotica Pharmaceuticals plc and Rexahn Pharmaceuticals Inc.
Table 2 shows Osmotica Pharmaceuticals plc and Rexahn Pharmaceuticals Inc.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Osmotica Pharmaceuticals plc||-2.33%||0%||0%|
|Rexahn Pharmaceuticals Inc.||0.00%||-119.8%||-71.6%|
The Current Ratio and Quick Ratio of Osmotica Pharmaceuticals plc are 1.3 and 1.1 respectively. Its competitor Rexahn Pharmaceuticals Inc.’s Current Ratio is 4.1 and its Quick Ratio is 4.1. Rexahn Pharmaceuticals Inc. can pay off short and long-term obligations better than Osmotica Pharmaceuticals plc.
Institutional and Insider Ownership
The shares of both Osmotica Pharmaceuticals plc and Rexahn Pharmaceuticals Inc. are owned by institutional investors at 51.5% and 9.3% respectively. Insiders held roughly 42.7% of Osmotica Pharmaceuticals plc’s shares. Competitively, 0.2% are Rexahn Pharmaceuticals Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Osmotica Pharmaceuticals plc||0.84%||-8.42%||5.43%||0%||0%||-7.35%|
|Rexahn Pharmaceuticals Inc.||3.48%||-16.3%||-51.51%||-67.96%||-65.28%||-42.13%|
For the past year Osmotica Pharmaceuticals plc was less bearish than Rexahn Pharmaceuticals Inc.
Osmotica Pharmaceuticals plc beats Rexahn Pharmaceuticals Inc. on 7 of the 9 factors.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companyÂ’s clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.